stoxline Quote Chart Rank Option Currency Glossary
  
Myomo, Inc. (MYO)
6.29  0.32 (5.36%)    02-12 16:00
Open: 5.91
High: 6.3325
Volume: 373,847
  
Pre. Close: 5.97
Low: 5.91
Market Cap: 209(M)
Technical analysis
2025-02-12 4:46:40 PM
Short term     
Mid term     
Targets 6-month :  7.65 1-year :  8.37
Resists First :  6.55 Second :  7.17
Pivot price 6.05
Supports First :  5.55 Second :  4.62
MAs MA(5) :  6.12 MA(20) :  6.06
MA(100) :  5.15 MA(250) :  4.27
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  61.7 D(3) :  59.9
RSI RSI(14): 55.5
52-week High :  7.17 Low :  2.51
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MYO ] has closed below upper band by 16.5%. Bollinger Bands are 27.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.35 - 6.39 6.39 - 6.43
Low: 5.81 - 5.86 5.86 - 5.91
Close: 6.21 - 6.29 6.29 - 6.37
Company Description

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Headline News

Wed, 05 Feb 2025
Rosalind Advisors, Inc. Increases Stake in Myomo Inc. - GuruFocus.com

Fri, 24 Jan 2025
Revisiting Myomo: Valuation Reflects High Growth, But Execution Matters (NYSE:MYO) - Seeking Alpha

Thu, 05 Dec 2024
Myomo Announces $15M Public Offering to Fuel Growth and Product Innovation - StockTitan

Thu, 05 Dec 2024
Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock - Business Wire

Wed, 04 Dec 2024
Myomo Launches Public Offering to Fuel Growth, Product Development & Market Expansion - StockTitan

Wed, 06 Nov 2024
Myomo Reports Record Third Quarter Financial and Operating Results - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
AMEX
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 30 (M)
Shares Float 16 (M)
Held by Insiders 13 (%)
Held by Institutions 47.6 (%)
Shares Short 938 (K)
Shares Short P.Month 714 (K)
Stock Financials
EPS -0.28
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.31
Profit Margin -44.8 %
Operating Margin -14.9 %
Return on Assets (ttm) -40.2 %
Return on Equity (ttm) -102.2 %
Qtrly Rev. Growth 26.2 %
Gross Profit (p.s.) 0
Sales Per Share 0.69
EBITDA (p.s.) -0.31
Qtrly Earnings Growth 0 %
Operating Cash Flow -9 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -23.3
PEG Ratio 45.9
Price to Book value 19.65
Price to Sales 9
Price to Cash Flow -20.61
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android